{
    "2021-05-01": [
        [
            {
                "time": "",
                "original_text": "国元证券维持华熙生物买入评级：产能产品不断壮大，业绩持续高速增长",
                "features": {
                    "keywords": [
                        "华熙生物",
                        "买入评级",
                        "产能",
                        "产品",
                        "业绩",
                        "高速增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "玻尿酸食品化，华熙生物的下一个故事不好讲",
                "features": {
                    "keywords": [
                        "玻尿酸",
                        "食品化",
                        "华熙生物",
                        "故事",
                        "不好讲"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "消费品"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}